Puretech Health Stock Price, News & Analysis

PureTech Health (NASDAQ: PRTC) presented compelling Phase 2b ELEVATE IPF trial data for deupirfenidone in idiopathic pulmonary fibrosis (IPF) at the 2025 IPF Summit in Boston. The trial demonstrated that deupirfenidone 825 mg TID reduced lung function decline by 80.9% versus placebo, showing approximately 50% greater treatment effect than pirfenidone.

Key findings include sustained efficacy through 52 weeks in the open-label extension study, with patients experiencing only a -32.8 mL decline in FVC, similar to natural decline in healthy older adults. The company also revealed that 69% of IPF patients in preference studies favored treatments offering greater efficacy over improved tolerability.

PureTech's newly launched Founded Entity, Celea Therapeutics, will advance deupirfenidone into Phase 3 trials, positioning it as a potential new standard of care in IPF treatment.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) has scheduled the release of its half-yearly results for the period ending June 30, 2025, to be announced on Thursday, August 28, 2025. The company will host a presentation and conference call for analysts and shareholders at 9:00 AM EDT / 2:00 PM BST on the same day. Interested parties can access the presentation webcast through PureTech's investor relations website.

Vedanta Biosciences, a PureTech (NASDAQ: PRTC) Founded Entity, announced that its Phase 2 COLLECTiVE202 study of VE202 for ulcerative colitis (UC) treatment failed to meet its primary endpoint of endoscopic response. While the treatment was well-tolerated with no serious adverse events, the response rates were not statistically different from placebo.

The company will now focus on its lead program VE303, currently in Phase 3 trials for recurrent Clostridioides difficile infection (CDI). VE303 previously showed promising Phase 2 results with a 30.5% absolute risk reduction compared to placebo. The program has received Fast Track and Orphan Drug designations from the FDA. Additionally, Vedanta is advancing VE707 for preventing multidrug-resistant infections, with an IND submission planned for 2026.

PureTech Health (NASDAQ: PRTC) has announced the launch of Celea Therapeutics, a new Founded Entity focused on developing treatments for serious respiratory diseases. The company's lead program, deupirfenidone (LYT-100), is Phase 3-ready and targets idiopathic pulmonary fibrosis (IPF), a rare and fatal lung disease.

Former Teva North America CEO Sven Dethlefs, PhD, has been appointed to lead Celea. Dr. Dethlefs brings over 25 years of pharmaceutical experience, including successful commercialization of AUSTEDO®, a deuterated medicine similar to deupirfenidone. The company recently completed a successful Phase 2b trial of deupirfenidone in December 2024, with FDA discussions expected by Q3 2025.

PureTech is seeking third-party funding to advance the program through Phase 3 and potential commercialization, aligned with its capital-efficient innovation model.

PureTech Health's (NASDAQ: PRTC) Founded Entity, Seaport Therapeutics, has initiated dosing in its Phase 2b BUOY-1 clinical trial for GlyphAllo™ (SPT-300), targeting Major Depressive Disorder (MDD). The study will evaluate approximately 360 patients over a six-week treatment period, with a primary focus on the Hamilton Depression Rating Scale-17.

GlyphAllo, a novel oral prodrug of allopregnanolone, demonstrated promising results in earlier trials, showing 9x greater allopregnanolone exposure compared to previous oral dosing methods. In Phase 2a, the drug significantly reduced stress hormone cortisol levels (p=0.0001) and was generally well-tolerated. The treatment targets the 280 million people globally affected by MDD, of whom 60% experience anxious distress.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) announced a significant leadership transition as CEO Bharatt Chowrira, PhD, JD, has stepped down from his position and Board membership after eight years with the company. The Board has appointed Robert Lyne as Interim CEO, effective immediately.

Lyne, who joined PureTech as Chief Portfolio Officer in January 2024, brings extensive experience in UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. The transition comes at a crucial time as the clinical-stage biotherapeutics company continues to advance its programs and focus on creating value for patients and shareholders.

PureTech's (Nasdaq: PRTC) Founded Entity Vor Bio (Nasdaq: VOR) has secured an exclusive global license agreement with RemeGen for telitacicept, a novel dual-target fusion protein, along with a $175 million private placement. The license agreement grants Vor Bio rights outside Greater China and includes an initial payment of $125 million ($45M upfront + $80M in warrants), with potential regulatory and commercial milestones exceeding $4 billion plus tiered royalties.

Telitacicept, already approved in China for multiple autoimmune conditions, is currently in global Phase 3 trials with results expected in H1 2027. Additionally, Vor Bio appointed Dr. Jean-Paul Kress as CEO and Chairman, replacing Dr. Robert Ang.

The private placement involves issuing warrants for 700 million shares at $0.25 per warrant, closing expected on June 27, 2025.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) held its Annual General Meeting on June 16, 2025, where all proposed resolutions were successfully passed. Notable outcomes include the approval of the 2024 Annual Report with 99.97% support, and the re-election of multiple directors including Dr. Robert Langer (95.43% approval) and Dr. Raju Kucherlapati (90.88% approval). Two resolutions received less than 80% approval: the Directors' Remuneration Report (72.49%) and the re-election of Ms. Kiran Mazumdar-Shaw (72.65%). The Board acknowledged these results and committed to continued shareholder engagement, promising an update within six months. Other key approvals included PricewaterhouseCoopers LLP's reappointment as auditors, authorization for share allotment, and approval for market purchase of own shares.

PureTech Health (PRTC) presented promising Phase 2b ELEVATE IPF trial results for deupirfenidone (LYT-100) at the 2025 ATS Conference. The drug demonstrated significant efficacy in treating idiopathic pulmonary fibrosis (IPF). At 825 mg TID dosing, deupirfenidone showed an 80.9% treatment effect vs. placebo, approximately 50% greater than pirfenidone's 54.1% effect. The drug slowed lung function decline to -21.5 mL over 26 weeks and preliminary 52-week data showed -32.8 mL decline, comparable to healthy older adults' natural decline. Importantly, deupirfenidone maintained favorable tolerability despite 50% higher drug exposure compared to pirfenidone. PureTech plans to meet with the FDA by Q3 2025 and aims to initiate Phase 3 trials by year-end.